StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN)

Investment analysts at StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a note issued to investors on Wednesday. The firm set a “sell” rating on the stock.

Oragenics Trading Down 6.0 %

Shares of OGEN stock opened at $0.27 on Wednesday. Oragenics has a 1 year low of $0.25 and a 1 year high of $7.74. The firm’s 50 day moving average is $0.37 and its 200-day moving average is $1.01. The firm has a market capitalization of $3.30 million, a price-to-earnings ratio of -0.04 and a beta of 0.49.

Institutional Investors Weigh In On Oragenics

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC bought a new position in shares of Oragenics, Inc. (NYSE:OGEN) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned about 0.51% of Oragenics at the end of the most recent quarter. Hedge funds and other institutional investors own 18.71% of the company’s stock.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.